FDA spurns CytoDyn’s HIV drug because of missing info

CytoDyn rejected by the FDA

CytoDyn rejected by the FDA.

The FDA rejected CytoDyn’s application for its lead program, an antibody to treat HIV in combination with antiretroviral therapy, because it’s missing some information, the company announced on Monday—two months after it revealed it had previously sent the wrong datasets to the agency.

The agency said in a refusal-to-file letter that the Biologics License Application (BLA) for leronlimab “does not contain certain information needed to complete a substantive review,” according to a CytoDyn statement. The Vancouver, Washington-based company did not specify what that information was but expressed confidence that it could produce what the agency wanted.

CytoDyn doesn’t need to carry out more clinical trials to fulfill the FDA’s request, the company said, adding that it would further analyze data from trials it has already finished.

The company’s stock dropped 9% Monday morning on the news before rebounding, but it closed at $3.70, down more than 20% from Friday’s closing price.

CytoDyn says it’s developing leronlimab for various diseases, including breast cancer, graft versus host disease, nonalcoholic steatohepatitis (NASH) and—you guessed it—COVID-19. It announced in April that the BLA for the antibody as a treatment for HIV infection was complete, but backtracked in May, saying it actually had been incomplete until then. The reason? It had included “mock datasets” instead of “clinical datasets.”

In the Monday statement, CytoDyn CEO Nader Pourhassan, Ph.D., pivoted from HIV to COVID-19: “We are 100% committed and confident we can provide the necessary information to the FDA as soon as possible. No additional trials will be required and all the information the FDA has requested is obtainable. While we await upcoming results in our two major COVID-19 Phase 2 and Phase 3 trials, we are confident July will be very important month for our shareholders.”

The company is testing the antibody against placebo in a phase 2b/3 study in 390 patients after having provided the drug to 54 patients with severe COVID-19 infection under an Emergency Investigational New Drug application from the FDA. It also has a phase 2 study underway in patients with mild to moderate disease.

SoftBank agreed on Tuesday to pay more than 10,000 million dollars to acquire WeWork, doubling its investment and paying close Read more

Microsoft has struck the table when it won the JEDI contract (acronym for Joint Enterprise Defense Infrastructure) tendered by the Read more

Siemens Gamesa has received a conditional order to supply 140 wind turbines of its most powerful model (11 MW) to Read more

A few years ago Boeing was the most important aeronautical company on the planet. being the most important civil constructor Read more

Tesla will begin delivering the first orders of the Model Y, its new SUV compact SUV, in the first quarter Read more

General Motors has announced that it will invest 1,500 million dollars (1,350 million euros) in the new generation of ‘pick-ups’ Read more

Netflix already has 158.3 million subscribers worldwide, demonstrating its strength in the face of increasing competition. However, its biggest advantage Read more

The aircraft manufacturer Boeing (NYSE: BA) suspends the production of its 737 MAX aircraft, after not obtaining this year, as Read more

Navin Shenoy, the vice president of Intel, said in a statement that “this acquisition advances our artificial intelligence strategy, which Read more

The Starliner spacecraft, from the Boeing company, landed successfully this Sunday in New Mexico after it failed on Friday in Read more

Leave a Reply